Penserra Capital Management’s abrdn Life Sciences Investors HQL Stock Holding History

Penserra Capital Management’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.8M	Buy	838,890 +32,002	+4%	+$566K	0.13%	172
2026 Q1	$13.1M	Sell	806,888 -68,238	-8%	-$1.14M	0.15%	171
2025 Q4	$14.7M	Buy	875,126 +80,988	+10%	+$1.36M	0.17%	153
2025 Q3	$12.3M	Buy	794,138 +24,481	+3%	+$335K	0.15%	161
2025 Q2	$9.86M	Buy	769,657 +22,736	+3%	+$280K	0.14%	184
2025 Q1	$9.48M	Sell	746,921 -80,654	-10%	-$1.09M	0.17%	161
2024 Q4	$10.9M	Buy	827,575 +51,573	+7%	+$744K	0.2%	151
2024 Q3	$11.7M	Buy	+776,002	New	+$11.7M	0.25%	97

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Penserra Capital Management's HQL Position: Q2 2026 in Review

Penserra Capital Management increased its abrdn Life Sciences Investors (HQL) stake by 4% in Q2 2026, buying an estimated $566K and bringing the position to 838,890 shares worth $16.8M. The position accounts for 0.13% of the portfolio, ranked #172.

Penserra Capital Management first reported a position in HQL in Q3 2024 and has held it in 8 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Penserra Capital Management held 838,890 shares of abrdn Life Sciences Investors worth $16.8M as of Q2 2026.
Penserra Capital Management bought 32,002 abrdn Life Sciences Investors shares in Q2 2026, an estimated $566K.
abrdn Life Sciences Investors made up 0.13% of Penserra Capital Management's portfolio in Q2 2026, its #172 holding.
Penserra Capital Management first reported a position in abrdn Life Sciences Investors in Q3 2024 and has held it in 8 quarters since.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.